Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles

Bristol-Myers Squibb, Pfizer, Biomarin and Sarepta are just a few of the biopharma players expected to make big strides in gene and cell therapies in 2020. But as these companies continue to produce treatments with disease-modifying or even lifesaving benefits for patients, they'll have to address challenges in everything from manufacturing to reimbursement.